IMAGE: Lung squamous cell carcinoma

Breaking News

Key: Meeting M      Journal J      Funder F

Showing releases 126-150 out of 1275.

<< < 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 > >>

Public Release: 12-Nov-2014
Environmental Science & Technology
A previously unrecognized flame retardant found in Americans for the first time
This is the first study to find the carcinogenic flame retardant TCEP in the bodies of Americans. It's also the first study to evaluate urinary levels of several phosphate flame retardant metabolites, like TCEP, which have been largely under the radar. Six metabolites were found in urine samples from California residents. People with the highest metabolite levels of two carcinogenic flame retardants also had the highest levels in their house dust, which were previously tested.
NIH/National Institute of Environmental Health Sciences, New York Community Trust, Fine Fund, Art beCAUSE Breast Cancer Foundation

Contact: Amelia Jarvinen
jarvinen@silentspring.org
617-332-4288 x226
Silent Spring Institute

Public Release: 12-Nov-2014
JAMA Surgery
Quarter of patients have subsequent surgery after breast conservation surgery
Nearly one-quarter of all patients who underwent initial breast conservation surgery for breast cancer had a subsequent surgical intervention, according to a report published online by JAMA Surgery.

Contact: Susan L. Smith
SSmith5@uwhealth.org
608-890-5643
The JAMA Network Journals

Public Release: 11-Nov-2014
RSNA 2014 100th Scientific Assembly and Annual Meeting
Tumor-analysis technology enables speedier treatment decisions for bowel-cancer patients
Technology developed at the University of Sussex helps hospitals make earlier and more accurate treatment decisions and survival assessments for patients with bowel cancer.

Contact: James Hakner
press@sussex.ac.uk
44-127-367-8888
University of Sussex

Public Release: 11-Nov-2014
Journal of Nuclear Medicine
Novel molecular imaging drug offers better detection of prostate cancer
A novel study demonstrates the potential of a novel molecular imaging drug to detect and visualize early prostate cancer in soft tissue, lymph nodes and bone. The research, published in the November issue of the Journal of Nuclear Medicine, compares the biodistribution and tumor uptake kinetics of two Tc-99m labeled ligands, MIP-1404 and MIP-1405, used with SPECT and planar imaging.

Contact: Kimberly Brown
kbrown@snmmi.org
703-652-6773
Society of Nuclear Medicine

Public Release: 11-Nov-2014
Journal of Biological Chemistry
Penn Vet team pieces together signaling pathway leading to obesity
A team of researchers led by the University of Pennsylvania School of Veterinary Medicine's Kendra K. Bence have now drawn connections between known regulators of body mass, pointing to possible treatments for obesity and metabolic disorders.
National Institutes of Health, Penn's Institute for Diabetes, Obesity and Metabolism

Contact: Katherine Unger Baillie
kbaillie@upenn.edu
215-898-9194
University of Pennsylvania

Public Release: 11-Nov-2014
Molecular Cancer Therapeutics
Next-gen melanoma drug, TAK-733, excels in lab tests
A University of Colorado Cancer Center study published online this week in the journal Molecular Cancer Therapeutics reports anti-cancer activity in 10 out of 11 patient tumor samples grown in mice and treated with the experimental drug TAK-733, a small molecule inhibitor of MEK1/2.

Contact: Garth Sundem
garth.sundem@ucdenver.edu
University of Colorado Denver

Public Release: 10-Nov-2014
Cancer
Physicians play a critical role in ensuring bladder cancer patients
When bladder cancer patients are well-informed by their physicians, they acknowledge that tobacco use was likely the cause of their disease.

Contact: Evelyn Martinez
sciencenewsroom@wiley.com
Wiley

Public Release: 10-Nov-2014
Cancer Cell
Classification of gene mutations in a children's cancer may point to improved treatments
Oncology researchers studying gene mutations in the children's cancer neuroblastoma are refining their diagnostic tools to predict which patients are more likely to respond to drugs called ALK inhibitors that target such mutations.
National Institutes of Health, US Army Peer-Reviewed Medical Research Program, National Science Foundation

Contact: Rachel Salis-Silverman
Salis@email.chop.edu
267-426-6063
Children's Hospital of Philadelphia

Public Release: 10-Nov-2014
Oncogene
Molecular breakthrough could halt the spread of prostate cancer
Scientists believe a new treatment, shown to be effective in mice, could halt the growth of tumours in patients with prostate cancer.
Prostate Cancer UK, Biotechnology and Biological Sciences Research Council

Contact: Philippa Walker
philippa.walker@bristol.ac.uk
44-117-928-8086
University of Bristol

Public Release: 10-Nov-2014
Cancer Cell
Researchers find new target for kidney cancer therapy
Cincinnati Cancer Center researchers have discovered that a membrane channel, Transient Receptor Potential Melastatin 3, or TRPM3, promotes growth of kidney cancer tumors, and targeting this channel therapeutically could lead to more treatments for a disease that currently has few treatment options.
National Institutes of Health, Veterans Affairs Merit Award, UC Center for Environmental Genetics Award

Contact: Katie Pence
katie.pence@uc.edu
513-558-4561
University of Cincinnati Academic Health Center

Public Release: 10-Nov-2014
Journal of Clinical Oncology
Half of premature colorectal cancer deaths due to socioeconomic inequality
Half of all premature deaths from colorectal cancer -- described as deaths in people ages 25 to 64 -- in the United States are linked to ethnic, socioeconomic, and geographic inequalities, and therefore could be prevented according to a new study by American Cancer Society researchers.
American Cancer Society

Contact: David Sampson
david.sampson@cancer.org
American Cancer Society

Public Release: 10-Nov-2014
Annals of Family Medicine
November/December 2014 Annals of Family Medicine tip sheet
This tip sheet features synopses of original research and commentary featured in the November/December issue of Annals of Family Medicine.

Contact: Angela Sharma
asharma@aafp.org
913-269-2269
American Academy of Family Physicians

Public Release: 10-Nov-2014
Cancer Cell
Scientists solve mystery of 'Frankenstein' DNA
Australian researchers have uncovered how the massive DNA molecules that appear in some tumours are formed like Frankenstein's monster, stitched together from other parts of the genome. This solves a decades-old mystery and explains how these tumours ensure their own survival.
National Health and Medical Research Council, Government of Victoria

Contact: Alison Heather
a.heather@garvan.org.au
61-292-958-128
Garvan Institute of Medical Research

Public Release: 10-Nov-2014
Cancer Discovery
Mayo Clinic researchers identify first steps in formation of pancreatic cancer
Researchers at Mayo Clinic's campus in Jacksonville say they have identified first steps in the origin of pancreatic cancer and that their findings suggest preventive strategies to explore.
National Institutes of Health

Contact: Kevin Punsky
punsky.kevin@mayo.edu
904-953-0746
Mayo Clinic

Public Release: 10-Nov-2014
Journal of Clinical Investigation
Tumor-associated neutrophils boost anti-tumor immune responses
A new study in the Journal of Clinical Investigation suggests that tumor-associated neutraphils help bolster the immune response against lung tumors.
National Institutes of Health, Janssen Pharmaceuticals, Lung Cancer Translation Center of Excellence of the Abramson Cancer Center at the University of Pennsylvania

Contact: Corinne Williams
press_releases@the-jci.org
Journal of Clinical Investigation

Public Release: 10-Nov-2014
Journal of Clinical Oncology
Smoking associated with elevated risk of developing a second smoking-related cancer
Results of a federally-funded pooled analysis of five prospective cohort studies indicate that cigarette smoking prior to the first diagnosis of lung (stage I), bladder, kidney or head and neck cancer increases risk of developing a second smoking-associated cancer. This is the largest study to date exploring risk of second cancers among current smokers.
NIH/National Cancer Institute

Contact: Kate Blackburn
kate.blackburn@asco.org
571-483-1379
American Society of Clinical Oncology

Public Release: 10-Nov-2014
Journal of Thoracic Oncology
Interstitial lung disease is a significant risk factor for lung inflammation
Pretreatment interstitial lung disease is a significant risk factor for developing symptomatic and severe radiation pneumonitis in stage I non-small cell lung cancer patients treated with stereotactic body radiation therapy alone.

Contact: Murry W. Wynes
murry.wynes@iaslc.org
720-325-2945
International Association for the Study of Lung Cancer

Public Release: 10-Nov-2014
New England Journal of Medicine
Lung cancer screening with low-dose CT could be cost effective says Dartmouth study
Dartmouth researchers say lung cancer screening in the National Lung Screening Trial meets a commonly accepted standard for cost effectiveness as reported in the Nov. 6 issue of the New England Journal of Medicine. This relatively new screening test uses annual low-dose CT scans to spot lung tumors early in individuals facing the highest risks of lung cancer due to age and smoking history.
NIH/National Cancer Institute

Contact: Rick Adams
Clarence.R.Adams@hitchcock.org
603-653-1910
The Geisel School of Medicine at Dartmouth

Public Release: 10-Nov-2014
Journal of Women's Health
New approach helps women talk to their families about cancer risk
To understand their risk for hereditary forms of cancer, such as breast and colon cancer, women need to know their family history. The design and effectiveness of a 20-minute skills-based intervention that can help women better communicate with relatives and gather and share information about cancer family history is described in a study in Journal of Women's Health.

Contact: Kathryn Ryan
kryan@liebertpub.com
914-740-2100
Mary Ann Liebert, Inc./Genetic Engineering News

Public Release: 10-Nov-2014
Blood
Researchers discover new target for blood cancer treatment
Scientists at the University of York have identified a therapeutic target which could lead to the development of new treatments for specific blood cancers.

Contact: David Garner
david.garner@york.ac.uk
44-019-043-22153
University of York

Public Release: 10-Nov-2014
JAMA Internal Medicine
ACP releases High Value Care advice for communicating about end-of-life care goals
Physician-patient communication about goals of care is a low risk, high value intervention for patients with a life threatening illness, the American College of Physicians advises in a paper published in JAMA Internal Medicine.

Contact: Steve Majewski
smajewski@acponline.org
American College of Physicians

Public Release: 7-Nov-2014
Oncotarget
A vaccine directed against tumor blood vessels suppress tumor growth and metastasis
In a new study published in the scientific journal Oncotarget researchers from Uppsala University show that a therapeutic vaccine directed against tumor vessels can reduce tumor burden and suppress formation of spontaneous lung metastases in a mouse model for metastatic breast cancer.

Contact: Anna-Karin Olsson
Anna-Karin.Olsson@imbim.uu.se
46-730-573-013
Uppsala University

Public Release: 7-Nov-2014
Cell
Researchers take new approach to stop 'most wanted' cancer protein
Researchers have found a way to defeat one of the most tantalizing yet elusive target proteins in cancer cells by turning the protein's own molecular machinations against it. They used a specially crafted compound to disrupt the protein's ability to rev up its own production and that of other proteins involved in tumor cell growth in an aggressive form of neuroblastoma. The resulting shrinkage of tumors caused little or no harm to normal cells.
National Institutes of Health, American Cancer Society, US Department of Defense, Friends for Life Neuroblastoma Foundation

Contact: Irene Sege
irene.sege@childrens.harvard.edu
617-919-3110
Dana-Farber Cancer Institute

Public Release: 7-Nov-2014
Journal of the American Board of Family Medicine
Nurse navigators may aid colon cancer screening follow-up
Group Health patients with a positive screening test for colon cancer (a stool test or sigmoidoscopy) tended to be more likely to get the recommended follow-up test, a diagnostic colonoscopy, if nurse navigators contacted them than if they got usual care, according to Beverly B. Green, MD, MPH, a Group Health physician and a Group Health Research Institute associate investigator.
NIH/National Cancer Institute

Contact: Joan DeClaire
declaire.j@ghc.org
206-287-2653
Group Health Research Institute

Public Release: 7-Nov-2014
Urology
Practice makes perfect in cancer surgery
In a new, in-depth research project, Queen's professors Rob Siemens, Urology, and Christopher Booth, Cancer Care and Epidemiology, investigated what affect higher volume hospitals and surgeons had on the outcomes of patients undergoing a radical cystectomy for bladder cancer in Ontario.

Contact: Anne Craig
anne.craig@queensu.ca
613-533-2877
Queen's University

Showing releases 126-150 out of 1275.

<< < 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 > >>

  Search News Releases

     

 

EurekAlert!